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Introduction
Breast cancer (BC) is the most common type of cancer and the leading cause of cancer
death among females globally.1 Hereditary factors are considered to play a key role in
the genesis of breast cancer. Among all breast carcinomas, about 5%–10% are inherited,
arising from genetic variants in susceptible genes.2,3 Single-nucleotide polymorphisms
(SNPs) are the most frequent variation that occur in a single nucleotide at a specific
position in the genome. Numerous SNPs have been identified through sequencing,
and many of them in critical genes such as BRCA1/2, TP53, TNF, and VEGF were
demonstrated to be associated with cancer susceptibility.4–6
FOXP3 is a protein-coding gene located at human chromosome Xp11.23. Its
product, forkhead box P3 (FoxP3), also known as scurfin, is specifically expressed in
CD4+CD25+ regulatory T cells (Tregs) and functions mainly as a key regulator for the
development and function of Tregs.7,8 As a member of the FOX family, FoxP3 also
regulates transcription and DNA repair and is involved in cell growth and differentiation
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Background: Forkhead box P3 (FOXP3) is a key gene in the immune system which also plays
a role in tumor development. This study aims to explore the association of two FOXP3 polymorphisms (rs3761548 and rs3761549) with susceptibility to breast cancer (BC).
Method: A case–control study was conducted, involving 560 patients and 583 healthy individuals from the Chinese Han population. The genotypes of FOXP3 polymorphisms were detected
using the Sequenom MassARRAY method. The association between FOXP3 polymorphisms
and BC risk was evaluated using a χ2 test with an odds ratio (OR) and 95% confidence intervals
(95% CIs) under six genetic models. False-positive report probability was utilized to examine
whether the significant findings were noteworthy.
Results: We observed that rs3761548 was associated with a higher BC risk in heterozygous,
dominant, overdominant, and allele genetic models (CA vs CC: OR =1.32, P=0.031; CA/AA
vs CC: OR =1.32, P=0.023; CA vs CC/AA: OR =1.29, P=0.042; A vs C: OR =1.26, P=0.029),
whereas no significant association was found between rs3761549 and BC risk. In addition, CA,
CA/AA genotype, and A allele of rs3761548 were related to larger tumor size, and the A allele
was also correlated with a positive status of Her-2 in BC patients.
Conclusion: Our study suggests that FOXP3 polymorphism rs3761548 is associated with
BC susceptibility in the Chinese and may be involved in tumor progression. Future studies are
needed to confirm the results in a larger population with more races.
Keywords: forkhead box P3, polymorphism, breast cancer, risk
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as well as embryogenesis.9,10 In addition to its critical function in immune response, FOXP3 plays an important role in
cancer development, although it is still a controversy whether
it is an oncogene or tumor suppressor gene.11,12
Nevertheless, several FOXP3 SNPs have been reported to
be associated with susceptibility to multiple cancers including
lung cancer, hepatocellular carcinoma (HCC), and colorectal
cancer.13–15 Among these SNPs, rs3761548 and rs3761549
were the most common polymorphisms. Studies revealed
that A allele and AA/AC genotype of rs3761548 significantly
increased the risk of thyroid cancer, colorectal cancer, and
non-small-cell lung cancer.13,15,16 T allele of rs3761549 was
found to be associated with susceptibility to lung cancer,
while C allele was related with higher risk of HCC. In addition, TT/CT genotype was linked to an increased incidence
of tumor recurrence in HCC.17,18 Here, we conducted a
case–control study to explore the association of the two
polymorphisms with BC risk in a Chinese Han population.

Methods
Study subjects
Cases were selected from female BC patients treated at the
Department of Oncology, the Second Affiliated Hospital
of Xi’an Jiaotong University (Xi’an, People’s Republic of
China). Healthy women who had a checkup at the hospital
during the same period of time were recruited as controls.
The criteria for enrollment were the same as our previous
study.19 Cases were confirmed by pathology, and controls
were matched according to age and menopausal status. None
of the cases had received chemotherapy or radiotherapy
before surgery. Patients with other types of cancer were
excluded. Finally, 560 patients and 583 healthy individuals
were enrolled in our study. All of the subjects were from the
Chinese Han population, had a mean age of 49 years, and
were not related to each other.

Ethics statement
This study was approved by the Ethics Committee of Xi’an
Jiaotong University. The purpose of this study was well
informed to the subjects and written informed consent was
obtained from each of them. Then, personal and clinical

information of the subjects was collected from their medical records.

Genotyping assay
Peripheral blood of each subject was collected in tubes
containing EDTA and stored at −80°C. Then, DNA was
extracted from whole blood using the Universal Genomic
DNA Extraction Kit (TaKaRa, Kyoto, Japan) according to
the manufacturer’s protocol, and the quantity of extracted
DNA was assessed utilizing the UV/Vis spectrophotometer (DU530, Beckman Instruments, Brea, CA, USA). Two
tag-SNPs (rs3761548 and rs3761549) were selected from
the HapMap database, with minor allele frequency (MAF)
>0.01 in Chinese Han population. Sequenom MassARRAY
Assay Design Software (version 3.0, Agena Bioscience, San
Diego, CA, USA) was used to design multiplexed SNP MassEXTEND assay. And SequenomMassARRAY RS1000 was
used to detect SNP genotyping.20 Primers of the two SNPs are
listed in Table 1. Data were analyzed with Sequenom Typer
Software (version 4.0, Sequenom, San Diego, CA, USA).

Statistical analysis
SPSS software (version 22.0, IBM Corporation, Armonk, NY,
USA) was used for statistical analyses of data. The differences
of basic parameters between the two groups were examined
with Student t-test or χ2 test. For each SNP, Hardy–Weinberg
equilibrium as well as the differences in allele frequencies
between patients and healthy controls were examined by χ2
test. The association of SNPs with BC risk was evaluated by
odds ratios (ORs) with 95% confidence intervals (CIs) for five
different genetic models (“A” indicates the major allele and
“a” indicates the minor allele): codominant model including
homozygote (aa vs AA) and heterozygote (Aa vs AA), dominant model (Aa/aa vs AA), recessive model (aa vs AA/Aa),
overdominant model (Aa vs AA/aa), and allele model (a vs A).
P-values were adjusted by logistic regression analysis. All the
tests were two-tailed, and P-value <0.05 was considered statistically significant. We further calculated false-positive report
probability (FPRP) to examine whether the significant findings
were noteworthy. The prior probability of 0.1 was set in our
study, and 0.5 was determined as a cut-off value for FPRP.21,22

Table 1 Primers used in this study
SNP_ID

1st-PCRP

2nd-PCRP

UEP_SEQ

rs3761548

ACGTTGGATGTGGGTGCTGAGGGGTAAACT

GCTCTCTCCCCAACTG

rs3761549

ACGTTGGATGACATCACCTACCACATCCAC

ACGTTGGATGAAGCCTAG
ATCTCAGGACTC
ACGTTGGATGACCCCACA
GGTTTCGTTCC

TTTCGTTCCGAGAACT

Abbreviations: SNP, single-nucleotide polymorphism; PCRP, primer for polymerase chain reaction; UEP_SEQ, primer for single nucleotide extension.
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Results
The basic characteristics of study
subjects

Association of FOXP3 SNPs with BC
susceptibility

No significant difference was observed between the two
groups in regards to age, menopausal status, and procreative
times. However, the mean value of body mass index (BMI) in
the patient group was significantly lower compared with that
in control group (P=0.038). As obesity is also associated with
BC risk,23 BMI may be a confounding factor for the analysis. Therefore, the results were adjusted for BMI. The basic
parameters of cases and controls are presented in Table 2.
Table 2 The comparison of basic characteristics between cases
and controls
Characteristics

Cases (560)

Controls (583)

P-value

Age (years, mean ± SD)
<49
≥49
Menopausal status
Premenopausal
Postmenopausal
Procreative times
<2
≥2
BMI (kg/m2, mean ± SD)

49.09±11.02
294
266

48.80±8.28
311
272

0.612

264
296

281
302

289
271

291
292

22.52±2.84

22.95±3.21

For both of the FOXP3 polymorphisms, the genotype distribution in controls complied with Hardy–Weinberg equilibrium
(P=0.895 and 0.934 respectively). In the overall analysis,
FOXP3-rs3761548 was associated with a higher BC risk in
heterozygous, dominant, overdominant, and allele genetic
models (CA vs CC: OR =1.32, 95% CI =1.03–1.69, P=0.031;
CA/AA vs CC: OR =1.32, 95% CI =1.04–1.69, P=0.023; CA
vs CC/AA: OR =1.29, 95% CI =1.01–1.66, P=0.042; A vs
C: OR =1.26, 95% CI =1.02–1.54, P=0.029). FPRP analysis
showed that the associations were noteworthy. However,
FOXP3-rs3761549 was not related to BC susceptibility
(Table 3). We then carried out stratified analysis based on
age and menopausal status in five genetic models. However,
no relationship was observed between the two SNPs and BC
susceptibility in either of the subgroups (Table S1).

0.716

0.594

0.038

Note: P-value <0.05 was shown in bold
Abbreviation: BMI, body mass index.

Relationship between FOXP3 SNPs and
clinical features of BC
We also explored the relationship between the two FOXP3
SNPs and BC clinical features, including tumor size, metastasis of lymph node, status of hormone receptor (estrogen
receptor and progesterone receptor) as well as Her-2, and

Table 3 Genotype frequencies of FOXP3 polymorphism in cases and controls
Model
rs3761548 (PHWE =0.895)
Codominant
Heterozygote
Homozygote
Dominant
Recessive
Overdominant
Allele
rs3761549 (PHWE=0.934)
Codominant
Heterozygote
Homozygote
Dominant
Recessive
Overdominant
Allele

Genotype
C/C
C/A
A/A
C/C
C/A+A/A
C/C+C/A
A/A
C/C+A/A
C/A
C
A
C/C
T/C
T/T
C/C
T/C-T/T
C/C-T/C
T/T
C/C-T/T
T/C
C
T

Cases (n, %)

Controls (n, %)

559
337 (60.3%)
198 (35.4%)
24 (4.3%)
337 (60.3%)
222 (39.7%)
535 (95.7%)
24 (4.3%)
361 (64.6%)
198 (35.4%)
872 (78.0%)
246 (22.0%)
560
385 (68.8%)
157 (28%)
18 (3.2%)
385 (68.8%)
175 (31.2%)
542 (96.8%)
18 (3.2%)
403 (72.0%)
157 (28.0%)
927 (82.8%)
193 (17.2%)

581
388 (66.8%)
173 (29.8%)
20 (3.4%)
388 (66.8%)
193 (33.2%)
561 (96.6%)
20 (3.4%)
408 (70.2%)
173 (29.8%)
949 (81.7%)
213 (18.3%)
582
372 (63.9%)
187 (32.1%)
23 (4.0%)
372 (63.9%)
210 (36.1%)
559 (96.0%)
23 (4.0%)
395 (67.9%)
187 (32.1%)
931 (80.0%)
233 (20.0%)

OR (95% CI)
1.00
1.32 (1.03–1.69)
1.38 (0.75–2.55)
1.00
1.32 (1.04-1.69)
1.00
1.26 (0.69–2.31)
1.00
1.29 (1.01–1.66)
1.00
1.26 (1.02–1.54)
1.00
0.81 (0.63–1.05)
0.76 (0.40–1.42)
1.00
0.81 (0.63–1.03)
1.00
0.81 (0.43–1.51)
1.00
0.82 (0.64–1.06)
1.00
0.83 (0.67–1.03)

Pa

FPRP

0.031
0.298

0.228

0.023

0.228

0.456
0.042

0.328

0.029

0.184

0.108
0.386
0.084
0.503
0.132
0.088

Note: aAdjusted for BMI. OR of significant association is presented in bold.
Abbreviations: BMI, body mass index; CI, confidence interval; FPRP, false-positive report probability; FOXP3, forkhead box P3; HWE, Hardy–Weinberg equilibrium; OR,
odds ratio.
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the expression level of Ki-67. We observed that CA, CA/AA
genotype, and A allele of rs3761548 were related with a larger
size of tumor (CA vs CC: OR =1.47, 95% CI =1.01–2.15;
CA/AA vs CC: OR =1.54, 95% CI =1.07–2.23; A vs C:
OR =1.48, 95% CI =1.08–2.03). In addition, the A allele was
correlated with a positive status of Her-2 (A vs C: OR =1.36,
95% CI =1.01–1.85) (Table 4). As for rs3761549, there was
still no significant association with BC clinicopathological
features existing in any of the genetic models (Table S2).

Discussion
FOXP3 is a key gene in the immune system. It encodes a
protein for a transcriptional regulator which belongs to the
forkhead/winged-helix family. Defects in this gene can cause
immunodeficiency syndrome.8,24 But the role of FOXP3 in
tumorigenesis has long been controversial. FOXP3 was
found to represses some oncogenes such as MYC, HER2, and
SATB1. Its expression was downregulated in several tumors
including breast, prostate, and ovarian tumors.11,12,25 However,
it was reported that most human tumors were inﬁltrated by
Tregs with high FoxP3 labeling, and an excess of Treg activity can prevent the immune system from destroying cancer
cells.26,27
No matter what the exact role of this gene in tumor is, the
genetic variation of FOXP3 can indeed affect cancer susceptibility.9,26 The two common polymorphisms rs3761549 (C>T)
and rs3761548 (C>A) were located in the promoter region of
the FOXP3 gene, which is considered to affect FoxP3 production and activity.14 They were investigated in several tumors
previously and were demonstrated to be associated with cancer susceptibility.13,15–18 However, the conclusions of the relationship between these two SNPs and BC susceptibility were
controversial. Lopes et al28 observed that the homozygote of

rs3761548 was associated with triple-negative breast cancer
risk in Brazilians (OR =3.78; 95% CI =1.02–14.06). Jahan
et al29 evaluated both rs3761548 and rs3761549 in an Indian
population but failed to find any correlation with BC risk.
However, the AA genotype of rs3761548 was significantly
associated with advanced tumor stage (T3-T4) (OR =3.90;
p=0.03),29 whereas Zheng et al’s30 and Raskin et al’s31 study
reported that neither rs3761548 nor rs3761549 were associated with BC. Among all these researchers, only Zheng et
al30 studied the Chinese population. However, their study
evaluated just two genetic models (homozygotes and heterozygotes) and did not explore the relationship of these two
SNPs with clinical parameters of BC.
Our study focused on a Chinese Han population and
found that the CA, CA/AA genotype, and the A allele of
rs3761548 can increase the risk of BC. Moreover, the A
allele of rs3761548 was related with a larger size of tumor
(≥2 cm). It was also correlated with a Her-2 positive status,
indicating that patients with A allele of rs3761548 are more
likely to have overexpression of HER2. It means that the
polymorphism of this locus may be a potential biomarker
for tumor subtype classification and help to guide treatment.
The results were in accord with some of previous studies,
suggesting that the A allele of rs3761548 is a risk factor for
BC and may be involved in tumor progression. The mechanism of action is not clear, which is a potential subject for
future studies. Maybe the critical location of this SNP could
affect the production and activity of FoxP3, thus influencing
tumorigenesis though FoxP3’s function.
Some limitations could not be ignored in the study. First,
selection bias is inevitable as this is a hospital-based, singlecenter study. Second, our sample size was insufficient to
support stratified analysis for tumor subtypes. Finally, we did

Table 4 The association between rs3761548 and clinical features of BC
Variables

OR (95% CI)
Homozygote

Tumor size
LN metastasis
ER
PR
Her-2
Ki-67

<2 cm
≥2 cm
(–)
(+)
(–)
(+)
(–)
(+)
(–)
(+)
<14%
≥14%

1.00
2.51 (0.83–7.64)
1.00
1.61 (0.59–4.40)
1.00
0.59 (0.26–1.36)
1.00
0.62 (0.30–1.27)
1.00
2.34 (0.96–5.69)
1.00
1.05 (0.41–2.690)

Heterozygote

Dominant

Recessive

Allele

1.47 (1.01–2.15)

1.54 (1.07–2.23)

2.19 (0.73–6.61)

1.48 (1.08–2.03)

1.28 (0.90–1.83)

1.31 (0.92–1.85)

1.47 (0.55–3.99)

1.26 (0.94–1.69)

0.76 (0.54–1.08)

0.74 (0.53–1.04)

0.66 (0.29–1.49)

0.77 (0.58–1.03)

0.77 (0.54–1.10)

0.75 (0.53–1.05)

0.68 (0.34–1.38)

0.78 (0.59–1.02)

1.29 (0.88–1.89)

1.37 (0.95–1.98)

2.13 (0.89–5.13)

1.36 (1.01–1.85)

0.96 (0.67–1.38)

0.97 (0.68–1.38)

1.07 (0.43–2.70)

0.98 (0.73–1.32)

Note: OR of significant association is presented in bold.
Abbreviations: BC, breast cancer; CI, confidence interval; ER, estrogen receptor; LN, lymph node; OR, odds ratio; PR, progesterone receptor.
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not analyze the impact of other risk factors such as lifestyle,
radiation exposure to the chest, family history, and other
benign breast lesions because of lacking relative data. Hence,
population-based studies are required in the future to improve
the accuracy of evaluation and to explore gene–environment
interactions as well.

Conclusion
To sum up, the present study suggests that the FOXP3 polymorphism rs3761548 is associated with BC susceptibility
in the Chinese and may be involved in tumor progression.
Future studies in a large population with more races are
needed to confirm the results. There is also a need to explore
gene–environment interactions and possible mechanisms of
action for this SNP.
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SNPs

Genotype

rs3761548
Age <49 (n=604)
Age ≥49 (n=536)
Premenopausal (n=544)
Postmenopausal
(n=596)
rs3761548
Age <49 (n=604)
Age ≥49 (n=538)
Premenopausal (n=544)
Postmenopausal
(n=598)

OR (95% CI)

Case (n=560)

Control
(n=583)

C/C
177
160
159
178

C/A
104
94
94
104

A/A
13
11
11
13

C/C
207
181
187
201

C/A
92
81
83
90

C/C
202
183
182
204

T/C
82
74
74
83

T/T
10
9
8
9

C/C
198
174
179
193

T/C
100
87
90
97

Homozygote

Heterozygote Dominant

Recessive

Allele

A/A
11
9
10
10

1.38 (0.60–3.16)
1.38 (0.56–3.42)
1.29 (0.54–3.13)
1.47 (0.63–3.43)

1.32 (0.94–1.87)
1.31 (0.91–1.89)
1.33 (0.93–1.92)
1.30 (0.92–1.85)

1.33 (0.95–1.85)
1.32 (0.93–1.88)
1.33 (0.94–1.88)
1.32 (0.95–1.85)

1.26 (0.55–2.85)
1.26 (0.51–3.09)
1.17 (0.49–2.81)
1.34 (0.58–3.11)

1.26 (0.95–1.67)
1.25 (0.93–1.69)
1.25 (0.93–1.68)
1.26 (0.95–1.68)

T/T
12
11
11
12

0.82 (0.35–1.93)
0.78 (0.31–1.92)
0.72 (0.28–1.82)
0.71 (0.29–1.72)

0.80 (0.57–1.14)
0.81 (0.56–1.17)
0.81 (0.56–1.17)
0.81 (0.57–1.15)

0.81 (0.57–1.13)
0.81 (0.56–1.15)
0.80 (0.56–1.14)
0.80 (0.57–1.12)

0.87 (0.37–2.06)
0.83 (0.34–2.04)
0.76 (0.30–1.93)
0.76 (0.31–1.83)

0.85 (0.63–1.13)
0.83 (0.61–1.13)
0.83 (0.61–1.12)
0.82 (0.61–1.10)

Abbreviations: BC, breast cancer; CI, confidence interval; FOXP3, forkhead box P3; OR, odds ratio; SNP, single-nucleotide polymorphism.

Table S2 The association between rs3761549 and clinical features of BC
Variables

OR (95% CI)
Homozygote

Tumor size
LN metastasis
ER
PR
Her-2
Ki-67

<2 cm
≥2 cm
(–)
(+)
(–)
(+)
(–)
(+)
(–)
(+)
<14%
≥14%

1.00
0.85 (0.28–2.59)
1.00
1.43 (0.63–3.25)
1.00
1.02 (0.40–2.59)
1.00
1.04 (0.35–3.07)
1.00
1.12 (0.33–3.79)
1.00
0.59 (0.26–1.36)

Heterozygote

Dominant

Recessive

Allele

0.84 (0.59–1.18)

0.84 (0.60–1.18)

0.91 (0.30–2.75)

0.87 (0.65–1.17)

0.74 (0.52–1.05)

0.81 (0.58–1.13)

1.66 (0.74–3.71)

0.92 (0.71–1.19)

1.26 (0.88–1.79)

1.24 (0.88–1.75)

0.97 (0.39–2.43)

1.15 (0.86–1.54)

0.84 (0.59–1.18)

0.85 (0.60–1.19)

1.12 (0.38–3.26)

0.90 (0.67–1.19)

0.95 (0.65–1.37)

0.95 (0.66–1.38)

1.14 (0.34–3.84)

0.98 (0.71–1.33)

0.72 (0.42–1.25)

0.68 (0.43–1.10)

0.62 (0.27–1.41)

0.68 (0.45–1.01)

Abbreviations: BC, breast cancer; CI, confidence interval; ER, estrogen receptor; LN, lymph node; OR, odds ratio; PR, progesterone receptor.
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